September 10, 2024

Anti-Seizure Drug Plus Omega-3 Show COVID-19—Related Benefits

Valproic acid users experienced a 25% lower risk of contracting COVID-19 and reduced disease severity among those who were infected, according to a study of over 3 million patients.

Conexiant

September 06, 2024

Cancer Diagnoses Lag Post-Pandemic, Study Reveals

Despite recovery efforts, U.S. cancer diagnoses remained 2.7% below expected levels in 2021, potentially leaving about 150,000 cases undetected over 2 years of COVID-19 pandemic–related disruptions.

Conexiant

September 06, 2024

WTC Study Reveals Epigenetic Cancer Risk Markers

World Trade Center exposure is linked to substantial DNA methylation changes, with 14.3% hypermethylated sites in exposed cancer-free individuals versus 4.5% in unexposed controls.

Conexiant

September 05, 2024

Youth E-Cigarette Use Plummeted in 2024

Youth e-cigarette use plummeted by 23.4% in 2024, with 500,000 fewer users compared to 2023, marking the lowest level in a decade and potentially signaling a shift in adolescent respiratory health trends.

Conexiant

September 03, 2024

Chronic Conditions Could Delay Lung Cancer Diagnoses

Investigators have assessed whether patients with certain chronic conditions may face delays in being diagnosed with lung cancer.

The ASCO Post

August 29, 2024

Under 30? ID Now Required for Cigarettes, Vapes

The FDA raises the minimum age for purchasing tobacco products, now requiring identification verification for individuals under 30 and prohibiting vending machine sales in the presence of individuals under 21.

Reuters

August 28, 2024

ICI-Based Strategies in Advanced, Progressing EGFR-Mutated NSCLC

Meta-analyses of trials of immune checkpoint inhibitors (ICIs) in patients with advanced EGFR-mutated NSCLC progressing on EGFR tyrosine kinase inhibitor treatment indicate that the optimal treatment ...

The ASCO Post

August 26, 2024

LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer

A subgroup analysis of data from the LIBRETTO-431 trial showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in E...

The ASCO Post

August 26, 2024

Study Reveals Tobacco Ad Exposure Disparities

Racial disparities emerge in TV and streaming platform tobacco ad exposure, with non-Hispanic Black adults reporting nearly double the exposure rate of their White counterparts, according to a new study.

Conexiant